Reuters: Merck hit hard by cholesterol drug rejection

[chris]

Merck hit hard by cholesterol drug rejection
      

NEW YORK (Reuters) - Confidence in Merck & Co's  earnings prospects withered on Tuesday, along with its stock price, after U.S. regulators surprisingly rejected the drugmaker's treatment to raise levels of "good" HDL cholesterol.
<p>You are not allowed to view links. Register or Login</p><div class="feedflare">
You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login
</div><img src="You are not allowed to view links. Register or Login" height="1" width="1"/>
      

You are not allowed to view links. Register or Login